lat1

LAT1-IN-1 (BCH) is a selective and competitive inhibitor of L-type amino acid transporter protein 1 (LAT1). LAT1-IN-1 has antitumor activity, inducing apoptosis in tumor cells and inhibiting cell proliferation.

JPH203 (KYT-0353) is a potent and specific inhibitor of L-type amino acid transporter protein 1 (LAT-1). JPH203 inhibits cellular uptake of leucine, inhibits cell proliferation, induces apoptosis, and possesses anti-inflammatory and anti-tumor activities.

MALAT1-IN-1 modulated Malat1 downstream genes in a dose-dependent manner without affecting the expression of nuclear enriched abundant transcript 1 (Neat1). MALAT1-IN-1 is an effective and specific Malat1 inhibitor.

JPH203 dihydrochloride (KYT-0353 dihydrochloride) is a tyrosine analog, acts as a selective inhibitor of L-type amino acid transporter 1 (LAT1), and is used in cancer research.

GPNA hydrochloride is specific glutamine (Gln) transporter ASCT2(SLC1A5) inhibitor. GPNA reversibly induces apoptosis in A549 cells. GPNA hydrochloride is a well-known substrate of the enzyme γ-glutamyltransferase (GGT). GPNA hydrochloride also inhibits

KMH-233 is a potent selective LAT1 inhibitor 1 that inhibits the uptake of LAT1 substrate, L-leucine, and cell growth. Even at low concentrations (25 μM), it significantly enhanced the efficacy of betastatin and cisplatin.

QBS10072S is a bifunctional chemotherapeutic agent that exerts its effects by combining a cytotoxin with a selective LAT1 transporter substrate. It demonstrates cytotoxicity in MDA-MB-231 cells and exhibits antitumor activity in mice. Additionally, QBS10072S possesses blood-brain barrier (BBB) permeability.

L-Citrulline (Standard) is available for quantitative analysis.) L-Citrulline is a non-essential amino acid involved in the nitric oxide cycle and the urea cycle, promotes vasodilatation, has antioxidant and anti-inflammatory properties, is orally available, and crosses the blood-brain barrier through LAT1. It is an agonist of eNOS (endothelial nitric oxide synthase), iNOS (inducible nitric oxide synthase), and mTORC1 (rapamycin targeting protein complex 1), and an inhibitor of SREBP-1 (sterol regulatory element binding protein 1).